These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors. Mesaros EF; Thieu TV; Wells GJ; Zificsak CA; Wagner JC; Breslin HJ; Tripathy R; Diebold JL; McHugh RJ; Wohler AT; Quail MR; Wan W; Lu L; Huang Z; Albom MS; Angeles TS; Wells-Knecht KJ; Aimone LD; Cheng M; Ator MA; Ott GR; Dorsey BD J Med Chem; 2012 Jan; 55(1):115-25. PubMed ID: 22141319 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401 [TBL] [Abstract][Full Text] [Related]
8. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors. Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217 [TBL] [Abstract][Full Text] [Related]
9. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. Harikrishnan LS; Kamau MG; Wan H; Inghrim JA; Zimmermann K; Sang X; Mastalerz HA; Johnson WL; Zhang G; Lombardo LJ; Poss MA; Trainor GL; Tokarski JS; Lorenzi MV; You D; Gottardis MM; Baldwin KF; Lippy J; Nirschl DS; Qiu R; Miller AV; Khan J; Sack JS; Purandare AV Bioorg Med Chem Lett; 2011 Mar; 21(5):1425-8. PubMed ID: 21282055 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors. Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718 [TBL] [Abstract][Full Text] [Related]
11. Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle. Ott GR; Favor DA Bioorg Med Chem Lett; 2017 Sep; 27(18):4238-4246. PubMed ID: 28801135 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors. Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-methyl-1-(beta-D-ribofuranosyl)- and 3-amino-5-methyl-1-(2-deoxy-beta-D-ribofuranosyl)-1,5-dihydro-1,4,5,6,7,8-hexaazaacenaphthylene as analogues of triciribine. Migawa MT; Drach JC; Townsend LB J Med Chem; 2005 Jun; 48(11):3840-51. PubMed ID: 15916436 [TBL] [Abstract][Full Text] [Related]
15. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223 [TBL] [Abstract][Full Text] [Related]
16. Metabolism of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): identification of an unusual N-acetylglucosamine conjugate in the cynomolgus monkey. Johnson BM; Kamath AV; Leet JE; Liu X; Bhide RS; Tejwani RW; Zhang Y; Qian L; Wei DD; Lombardo LJ; Shu YZ Drug Metab Dispos; 2008 Dec; 36(12):2475-83. PubMed ID: 18787055 [TBL] [Abstract][Full Text] [Related]
17. [Research on antineoplastic substances. LI. Derivatives of benzo(f)-pyrrolo-(1,2-a)-quinoxaline and naphtho-(2,1-e)-pyrrolo-(2,1-c)-as-triazine: synthesis and cytostatic and cytotoxic activity]. Chimenti F; Giuliano R; Vomero S; Artico M; Dolfini E; Morasca L Farmaco Sci; 1973; 28(4):284-97. PubMed ID: 4698886 [No Abstract] [Full Text] [Related]
18. Mechanistic studies on a P450-mediated rearrangement of BMS-690514: conversion of a pyrrolotriazine to a hydroxypyridotriazine. Hong H; Caceres-Cortes J; Su H; Huang X; Roongta V; Bonacorsi S; Hong Y; Tian Y; Iyer RA; Humphreys WG; Christopher LJ Chem Res Toxicol; 2011 Jan; 24(1):125-34. PubMed ID: 21080678 [TBL] [Abstract][Full Text] [Related]
19. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. Bhide RS; Cai ZW; Zhang YZ; Qian L; Wei D; Barbosa S; Lombardo LJ; Borzilleri RM; Zheng X; Wu LI; Barrish JC; Kim SH; Leavitt K; Mathur A; Leith L; Chao S; Wautlet B; Mortillo S; Jeyaseelan R; Kukral D; Hunt JT; Kamath A; Fura A; Vyas V; Marathe P; D'Arienzo C; Derbin G; Fargnoli J J Med Chem; 2006 Apr; 49(7):2143-6. PubMed ID: 16570908 [TBL] [Abstract][Full Text] [Related]
20. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase. Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]